-- DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be
available imminently, per the Accelerated Approval analysis and
regulatory submission plan previously communicated
-- Updated data timing driven by dialogue between Invivyd and the U.S. FDA
1) to refine details on the Accelerated Approval approach for VYD2311,
and 2) to expand the accelerated regulatory approach and enable rapid
development of future Invivyd monoclonal antibodies, including Invivyd's
measles antibody candidate; further update to be provided with
DECLARATION interim analysis data
-- Achieved Q3 2026 PEMGARDA(R) (pemivibart) net product revenue of $15.4
million, representing 18% growth versus Q3 2025 net product revenue of
$13.1 million
-- Appointed Chairman Marc W. Elia as Chief Executive Officer
-- Announced positive topline results from LIBERTY Phase 3 clinical trial,
which demonstrated VYD2311 safety and tolerability superior to an
mRNA-based COVID-19 vaccine and lack of interference with vaccine-induced
neutralizing antibody titers
-- Announced initiation of FLINTLOCK Phase 2 clinical trial of VYD2311,
which will evaluate VYD2311 in adults aged 18-65 years with Long COVID or
Post-Vaccination Syndrome, also known as COVID vaccine injury
-- Investments being made in commercial preparedness for VYD2311; Invivyd
plans to host a Medical and Commercial Investor Event in 1H 2027 to
describe commercial plans and early expressions of institutional demand
-- Q3 2026 ending cash and cash equivalents of $126.4 million
NEW HAVEN, Conn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the third quarter ended September 30, 2026, and recent business highlights.
"We are excited about the progress made to advance VYD2311 to meet the urgent need for new options to prevent Americans from getting sick from COVID and suffering from the debilitating impact of Long COVID or COVID vaccine injury," said Marc Elia, Chairman and Chief Executive Officer of Invivyd. "While our DECLARATION data readout timing has been updated as we continued to work with regulators and policymakers on immunization regulation in America broadly, we are pleased that U.S. regulators understand the important role monoclonal antibodies can play in infectious disease going forward. We look forward to providing DECLARATION data and a regulatory update imminently, and we appreciate investor patience as we endeavor to set the stage for anticipated rapid advancement should VYD2311 DECLARATION data demonstrate an attractive clinical profile."
"PEMGARDA's continued growth, even in the face of declining COVID vaccine utilization and announcement of the termination of its Emergency Use Authorization in mid-2027, demonstrates clear demand for monoclonal antibodies," commented Bill Duke, Chief Financial Officer of Invivyd. "With a bolus of REVOLUTION clinical program spend in the rear view at this time, we look forward to a new posture of increased operating efficiency while we work to bring VYD2311 to vulnerable Americans as fast as possible."
Third Quarter 2026 and Recent Company Highlights
PEMGARDA(R) Commercial Performance & Regulatory Update
-- PEMGARDA net product revenue was $15.4 million for the quarter ended
September 30, 2026, compared to $13.1 million for the quarter ended
September 30, 2025. Growth of 18% was driven primarily by increased
patient demand.
-- In July 2026, Invivyd announced receipt of twelve months' advanced notice
of emergency use authorization (EUA) termination for PEMGARDA and that
the company is in dialogue with the U.S. Food and Drug Administration
(FDA) about appropriate next steps.
Research & Development (R&D) Highlights
COVID-19
-- Invivyd continued to advance its REVOLUTION program, which is Invivyd's
development program for VYD2311 that is designed to elaborate the profile
of monoclonal antibody-mediated prophylaxis from COVID-19 and the
potential medical benefits to vulnerable Americans:
-- LIBERTY: In June 2026, Invivyd announced first participants dosed
and completion of enrollment in LIBERTY, a Phase 3 clinical trial
to evaluate the safety and tolerability of VYD2311 antibody versus
mRNA COVID vaccine and to characterize the safety and immunology
of antibody and mRNA vaccine co-administration. In September 2026,
Invivyd announced positive topline results from LIBERTY
demonstrating VYD2311 safety and tolerability superior to an
mRNA-based COVID-19 vaccine:
-- VYD2311 met all primary and secondary endpoints comparing
VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating
VYD2311 safety and tolerability that is clinically and
statistically superior to the safety and tolerability of an
mRNA-based COVID-19 vaccine.
-- VYD2311 combined with an mRNA-based COVID-19 vaccine
demonstrated no interference with vaccine-induced
neutralizing titers and instead added substantially to
vaccine-induced neutralizing titers.
-- VYD2311 observed profile in LIBERTY indicates high measured
neutralizing antiviral titers supporting the target profile
for VYD2311 under study in the DECLARATION pivotal clinical
study.
-- DECLARATION: In September 2026, Invivyd announced plans for the
DECLARATION Phase 3 clinical trial, with support from the LIBERTY
clinical trial and reference to prior Invivyd COVID-19 mAb data, to be
the basis of a planned Biologics License Application (BLA) submission for
VYD2311 to the FDA under the Accelerated Approval Program. Invivyd plans
to conduct a prespecified interim analysis in DECLARATION designed to
evaluate serum virus neutralizing antibody titers, pharmacokinetics,
immunogenicity, and safety of VYD2311, while keeping blinded the clinical
events collected to date. These analyses are intended to support a BLA
submission under the Accelerated Approval Program, with the interim data
expected imminently. Invivyd plans to continue the DECLARATION study to
serve as the confirmatory trial, with DECLARATION continuing to collect
RT-PCR-confirmed symptomatic COVID-19 events. Clinical event data from
DECLARATION will serve, if the study is positive, as confirmatory
evidence for conversion to traditional approval of VYD2311.
-- FLINTLOCK: In January 2026, Invivyd and the SPEAR (Spike Protein
Elimination and Recovery) Study Group announced the plan to initiate a
Phase 2 clinical trial evaluating VYD2311 in individuals with Long COVID
or COVID vaccine injury. In October 2026, Invivyd and the SPEAR Study
Group announced initiation of FLINTLOCK.
-- FLINTLOCK Phase 2 clinical trial will evaluate the safety,
tolerability, pharmacokinetics, and clinical efficacy of high-dose
VYD2311 in adults aged 18-65 years with Long COVID or
Post-Vaccination Syndrome, also known as COVID vaccine injury.
-- Design includes VYD2311 administered in three doses to assess the
safety and potential clinical benefit of VYD2311 treatment versus
placebo over 90 days.
Measles
-- In October 2026, Invivyd presented VMS063, a novel, potential first-and
best-in-class monoclonal antibody investigational candidate for the
treatment and prevention of measles, at IDWeek 2026(TM). VMS063
preclinical data has demonstrated potent in vitro antiviral activity
against contemporary measles virus variants and attractive biophysical
properties supporting its potential utility for both treatment and
prevention of measles. Invivyd is scaling up production toward clinical
development in 2027.
Corporate Updates
-- In September 2026, Invivyd announced the appointment of Marc Elia,
Chairman of Invivyd's Board of Directors (the Board), as Chief Executive
Officer of Invivyd. In addition, Invivyd announced Ajay Royan, Founder of
Mithril Capital, a founding, long-term investor of Invivyd, and a member
of the Board, was appointed as Lead Independent Director of the Board,
and Ian Sheffield was appointed to the Board as an independent director.
Third Quarter 2026 Financial Results
-- Revenue: Reported Q3 2026 PEMGARDA net product revenue of $15.4 million,
compared to $13.1 million in Q3 2025, representing an 18% increase.
-- Cash Position: Cash and cash equivalents were $126.4 million as of
September 30, 2026.
-- R&D Expenses: R&D expenses were $18.7 million for the quarter ended
September 30, 2026, compared to $8.0 million for the comparable period in
2025. This increase is primarily attributable to higher contract research
costs associated with the DECLARATION and LIBERTY clinical trials for
VYD2311.
-- Selling, General & Administrative (SG&A) Expenses: SG&A expenses were
$30.3 million for the quarter ended September 30, 2026, compared to $15.0
million for the comparable period in 2025. This increase is primarily
attributable to an increase in personnel, communications and
commercial-related costs.
-- Net Loss and Net Loss per Share: Net loss was $33.5 million for the
quarter ended September 30, 2026, compared to $10.5 million for the
comparable period in 2025. Basic and diluted net loss per share was $0.10
for the quarter ended September 30, 2026, compared to $0.06 for the
comparable period in 2025.
About PEMGARDA
Comments